Neurotrope Launches Long-term Trial of Bryostatin-1

Neurotrope Launches Long-term Trial of Bryostatin-1
Neurotrope has announced the launch of a Phase 2 clinical trial to investigate the long-term use of bryostatin-1 for moderate and moderately severe Alzheimer's disease The company expects to dose the first patient later this year. "We are very excited to advance Bryostatin-1 to its next phase of development," Daniel Alkon, MD, president and chief scientific officer of Neurotrope said in a press release. Bryostatin-1 is a small molecule designed to penetrate the blood-brain barrier and specifically activate the protein kinase C, which plays an important role in learning and memory, and in maintaining the health of synapses — junctions where nerve cells come into contact and communicate with each other. The new Phase 2 clinical trial intends to enroll approximately 100 patients with moderate and moderately severe Alzheimer's disease, as measured by
Subscribe or to access all post and page content.